ADMA Biologics Inc is trading 10% up at $8.80 in pre-market, driven by momentum and speculative interest as no fresh company-specific news has been reported this morning.
- The move extends a multi-day uptrend that has been building since late May.
- No recent earnings, FDA decisions, or major analyst calls have emerged to justify the current price action.
- The surge appears to be fueled by technical momentum rather than a confirmed fundamental catalyst.